Skip to main content
. Author manuscript; available in PMC: 2022 Sep 1.
Published in final edited form as: Am J Transplant. 2021 Mar 17;21(9):3066–3076. doi: 10.1111/ajt.16538

Figure 4. CD86 receptor occupancy.

Figure 4.

Whole blood was collected from healthy controls (HC), and q1m and q2m belatacept-treated transplant recipients before i.v. infusion (trough) and 30 minutes after infusion (post-dose). Samples were stained with HA5, an anti-CD86 mAb that competes with CTLA-4-Ig for CD86, and the amount of CD86 receptor saturation by belatacept on CD14+ monocytes was measured by HA5 MFI. Summary data represent mean (SE). * p <0.05, *** p <0.001.